



Exercise of options and PDMR dealing

December 7, 2023 9:50 AM EST

RNS Number : 0411W

MaxCyte, Inc.

07 December 2023

MaxCyte, Inc.

("MaxCyte" or the "Company")

Exercise of options and PDMR dealing

ROCKVILLE, MD, December 7, 2023: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that between 4 December 2023 and 5 December 2023, as per a filing lodged with the U.S. Securities and Exchange Commission, Doug Doerfler, Chief Executive Officer of the Company, exercised options over 124,450 shares of common stock of \$0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 124,450 new shares of Common Stock were issued pursuant to the Company's existing its block admission facility and were sold by Doug Doerfler at a price range between \$5.00 and \$5.27 per Common Stock ("Sale"). The sold shares represent approximately 3.5% of Doug Doerfler's total equity and option holdings in the Company's stock capital, respectively.

Following the Exercise and Sale, Doug Doerfler holds 333,197 shares of Common Stock representing 0.3% of the issued stock capital of the Company. Following the Exercise, Doug Doerfler holds a further 3,053,680 options over Common Stock.

The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by Doug Doerfler on 18 November 2022 relating solely to the sale of shares acquired from exercise of options that expire on 11 November 2024.

MaxCyte Contacts:

US IR Adviser

Gilmartin Group

+1 415-937-5400

David Deuchler, CFA

ir@maxcyte.com

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

+44 (0)20 7886 2500

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

UK IR Adviser

+44 (0)203 709 5700

ICR Consilium

maxcyte@consilium-comms.com

Mary-Jane Elliott

Chris Welsh

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on [Twitter](https://twitter.com/maxcyte) and [LinkedIn](https://www.linkedin.com/company/maxcyte).

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1 Details of the person discharging managerial responsibilities / person closely associated

a)Name Doug Doerfler

2 Reason for the notification

a)Position/status Chief Executive Officer

b)Initial notification /Amendment Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)Name MaxCyte Inc.

b)LEI 54930053YHXULRFCU991

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)Description of the financial instrument, type of instrument Common Stock of \$0.01 each

Identification code US57777K1060

b) Nature of the transaction	Exercise of Options over common stock	
c) Price(s) and volume(s)	Exercise Price(s)	Volume(s)
	\$0.04	25,008
d) Aggregated information		
- Aggregated volume	25,008	
- Price	\$0.04	
e) Date of the transaction	4 December 2023	
f) Place of the transaction	US Stock Exchange, Nasdaq	

1 Details of the person discharging managerial responsibilities / person closely associated

a) Name Doug Doerfler

2 Reason for the notification

a) Position/status Chief Executive Officer

b) Initial notification /Amendment Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)Name MaxCyte Inc.

b)LEI 54930053YHXULRFCU991

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)Description of the financial instrument, type of instrument Common Stock of \$0.01 each

Identification code US57777K1060

b)Nature of the transaction Sale of common stock

c)Price(s) and volume(s)

Exercise Price(s)	Volume(s)
\$5.0000	9,353
\$5.0050	10,177
\$5.0100	2,006
\$5.0150	1,987
\$5.0200	397
\$5.0250	799
\$5.0300	289

d)Aggregated information

- Aggregated volume 25,008

- Price \$5.0055

e)Date of the transaction 4 December 2023

f) Place of the transaction US Stock Exchange, Nasdaq

1 Details of the person discharging managerial responsibilities / person closely associated

a)Name Doug Doerfler

2 Reason for the notification

a)Position/status Chief Executive Officer

b)Initial notification /Amendment Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)Name MaxCyte Inc.

b)LEI 54930053YHXULRFCU991

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)Description of the financial instrument, type of instrument Common Stock of \$0.01 each

Identification code US57777K1060

b)Nature of the transaction Exercise of Options over common stock

c)Price(s) and volume(s)

Exercise Price(s)	Volume(s)
\$0.04	99,442

d) Aggregated information

- Aggregated volume 99,442

- Price \$0.04

e) Date of the transaction 5 December 2023

f) Place of the transaction US Stock Exchange, Nasdaq

1 Details of the person discharging managerial responsibilities / person closely associated

a) Name Doug Doerfler

2 Reason for the notification

a) Position/status Chief Executive Officer

b) Initial notification /Amendment Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name MaxCyte Inc.

b) LEI 54930053YHXULRFCU991

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)Description of the financial instrument, type of instrument

Common Stock of \$0.01 each

Identification code

US57777K1060

b)Nature of the transaction

Sale of common stock

c)Price(s) and volume(s)

Exercise Price(s)	Volume(s)
\$5.0000	203
\$5.0050	100
\$5.0200	599
\$5.0250	100
\$5.0300	92
\$5.0350	1,074
\$5.0400	463
\$5.0450	638
\$5.0500	2,066
\$5.0550	100
\$5.0600	1,064
\$5.0650	200
\$5.0700	790
\$5.0750	527
\$5.0800	2,216
\$5.0850	1,271
\$5.0900	977
\$5.0950	819
\$5.1000	1,921
\$5.1050	506
\$5.1100	593
\$5.1150	498
\$5.1200	774

\$5.1250	1,243
\$5.1300	4,002
\$5.1350	1,223
\$5.1400	1,037
\$5.1450	2,446
\$5.1500	9,198
\$5.1525	300
\$5.1550	2,963
\$5.1600	792
\$5.1650	729
\$5.1700	604
\$5.1750	2,949
\$5.1800	1,743
\$5.1850	2,913
\$5.1900	2,369
\$5.1950	5,449
\$5.2000	3,043
\$5.2050	2,019
\$5.2100	2,287
\$5.2150	16,700
\$5.2200	461
\$5.2250	900
\$5.2300	636
\$5.2350	1,700
\$5.2400	300
\$5.2450	9
\$5.2500	10,374
\$5.2550	771
\$5.2600	100
\$5.2650	2,200

\$5.2700

391

d)Aggregated information

- Aggregated volume

99,442

- Price

\$5.1737

e)Date of the transaction

5 December 2023

f) Place of the transaction

US Stock Exchange, Nasdaq

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHTRBLTMTIMMLJ